Key Takeaways
- • Almanac Health raised $10 million in a seed round led by F-Prime Capital, with participation from General Catalyst and Lightspeed Venture Partners, bringing total funding to nearly $12 million since inception.
- • The clinical AI platform is founded by physician-researcher Cyril Zakka, MD, whose Stanford work pioneered retrieval-augmented generation applications in clinical medicine, positioning the company at the intersection of validated research and practical clinical deployment.
- • The platform delivers specialist-grade clinical decision support integrated directly into existing EHR systems, designed with institutional governance controls and grounded exclusively in peer-reviewed evidence rather than general-purpose large language models.
- • Almanac Health is currently undergoing rigorous clinical validation in academic medical center settings, addressing the critical gap between AI hype in healthcare and evidence-based tools that clinicians can trust.
- • Funding will accelerate team expansion across clinical medicine, AI research, and health systems infrastructure, signaling venture investor confidence in the market demand for research-validated clinical AI with aligned incentives.
Summary
Almanac Health, a Boston-based clinical decision support platform, has secured $10 million in seed-stage funding led by F-Prime Capital, with participation from General Catalyst and Lightspeed Venture Partners. The investment brings the company's total capitalization to approximately $12 million. General Catalyst, which led an earlier pre-seed round alongside Soma Capital, has doubled down on the investment, reflecting sustained institutional confidence in the company's mission and execution trajectory.
The company is distinguished by its founding leadership and technical foundation. Cyril Zakka, MD, a physician-researcher, established Almanac Health after pioneering work at Stanford that introduced retrieval-augmented generation—a technique for grounding AI responses in external knowledge sources—to clinical medicine. This academic pedigree directly informs the platform's design philosophy: clinical AI validated through rigorous research rather than general-purpose models adapted to healthcare contexts.
Almanac Health's platform operates as a unified clinical AI system designed to embed specialist-level knowledge at the point of care within existing EHR workflows. The architecture prioritizes institutional control, peer-reviewed evidence grounding, and clinician-patient incentive alignment. Rather than replacing clinician judgment, the platform augments decision-making with evidence-based guidance accessible to specialists and generalists alike. The company is currently advancing clinical validation studies within academic medical centers, a methodologically rigorous approach that distinguishes it from competitors pursuing faster deployment timelines.
The capital deployment signals market recognition of a critical healthcare technology gap. As the company stated, "there is no shortage of technologies promising to transform medicine. But few are grounded in real evidence, built with integrity and deserving of trust from the people and organizations using them." This articulation captures institutional investor appetite for healthcare AI that prioritizes clinical safety and evidence validity over rapid scaling. The funding will support team expansion across clinical medicine, AI research, and health systems infrastructure—the operational components required to scale validated clinical AI across diverse institutional settings.
The company is distinguished by its founding leadership and technical foundation. Cyril Zakka, MD, a physician-researcher, established Almanac Health after pioneering work at Stanford that introduced retrieval-augmented generation—a technique for grounding AI responses in external knowledge sources—to clinical medicine. This academic pedigree directly informs the platform's design philosophy: clinical AI validated through rigorous research rather than general-purpose models adapted to healthcare contexts.
Almanac Health's platform operates as a unified clinical AI system designed to embed specialist-level knowledge at the point of care within existing EHR workflows. The architecture prioritizes institutional control, peer-reviewed evidence grounding, and clinician-patient incentive alignment. Rather than replacing clinician judgment, the platform augments decision-making with evidence-based guidance accessible to specialists and generalists alike. The company is currently advancing clinical validation studies within academic medical centers, a methodologically rigorous approach that distinguishes it from competitors pursuing faster deployment timelines.
The capital deployment signals market recognition of a critical healthcare technology gap. As the company stated, "there is no shortage of technologies promising to transform medicine. But few are grounded in real evidence, built with integrity and deserving of trust from the people and organizations using them." This articulation captures institutional investor appetite for healthcare AI that prioritizes clinical safety and evidence validity over rapid scaling. The funding will support team expansion across clinical medicine, AI research, and health systems infrastructure—the operational components required to scale validated clinical AI across diverse institutional settings.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.